E2F3 and pancreatic adenocarcinoma: In the Logsdon dataset (39), the expression of E2F3 in the two groups of PAAD was significantly up-regulated compared with normal samples, with fold changes of 1.551 (P = 0.001) and 1.963 (P = 4.87E-5), respectively (Table 1).